Phenothiazine derivative having a double bond, method for the production thereof, and use thereof as a pharmaceutical

1. A compound of formula I

wherein:

R1 is H, (C 1 -C 6 )-alkyl, (C 0 -C 6 )-alkylene-aryl, CO—(C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkylene-COO—(C 0 -C 6 )-alkyl, or (C 2 -C 6 )-alkylene-O—(C 1 -C 6 )-alkyl;

R2 and R3 are, independently, H, F, Cl, Br, CN, NO 2 , (C 0 -C 6 )-alkylene-COO—(C 0 -C 6 )-alkyl, (C 0 -C 6 )-alkylene-O—(C 0 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 0 -C 6 )-alkylene-CO—(C 1 -C 6 )-alkyl,(C 0 -C 6 )-alkylene-phenyl, SCF 3 , SF 5 , or SCH 3 ;

R4 and R5 are, independently, H, F, Cl, Br, CN, SCN, NO 2 , (C 0 -C 6 )-alkylene-COO—(C 0 -C 6 )-alkyl, —CO—COO—(C 0 -C 6 )-alkyl, (C 0 -C 6 )-alkylene-O—(C 0 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 0 -C 6 )-alkylene-CO—(C 1 -C 6 )-alkyl, (C 0 -C 6 )-alkylene-CONH(C 0 -C 6 )-alkyl, (C 0 -C 6 )-alkylene-CON[(C 0 -C 6 )-alkyl] 2 , (C 0 -C 6 )-alkylene-NH(C 0 -C 6 )-alkyl, (C 0 -C 6 )-alkylene-NH—COO—(C 0 -C 6 )-alkyl, (C 0 -C 6 )-alkylene-CON[(C 0 -C 6 )-alkyl]-O—(C 0 -C 6 )-alkyl, (C 0 -C 6 )-alkylene-N[(C 0 -C 6 )-alkyl] 2 , (C 0 -C 6 )-alkylene-aryl, SF 5 , (C 0 -C 6 )-alkyl-S(O) x (C 1 -C 6 )-alkyl, S(O) x (C 1 -C 6 )-alkylene-COO—(C 0 -C 6 )-alkyl, S(O) x (C 2 -C 6 )-alkylene-O—(C 0 -C 6 )-alkyl, —SO 2 —NH—(C 0 -C 6 )-alkyl, —SO 2 —N—[(C 0 -C 6 )-alkyl] 2 , S(O) x (C 0 -C 6 )-alkylene-heterocycle, S(O) x (C 1 -C 6 )-alkylene-CO-heterocycle, —NH—SO 2 —(C 1 -C 6 )-alkyl, (C 0 -C 6 )-alkylene-cycloalkyl, (C 0 -C 6 )-alkylene-heterocycle, or (C 0 -C 6 )-alkylene-aryl;

R6 and R7 are, independently, H, F, Cl, Br, CN, NO 2 , ═O, ═S, ═N—O—(C 0 -C 6 )-alkyl, (C 0 -C 6 )-alkylene-COO—(C 0 -C 6 )-alkyl, (C 0 -C 6 )-alkylene-O—(C 0 -C 6 )-alkyl, (C 0 -C 6 )-alkylene-O—CO—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 0 -C 6 )-alkylene-CO—(C 1 -C 6 )-alkyl,(C 0 -C 6 )-alkylene-aryl, SF 5 , or S(O) x —(C 1 -C 6 )-alkyl;

x is 0, 1 or 2;

A is a 5- to 10-membered heterocycle, wherein the heterocycle is optionally fused to a further 5- to 10-membered ring; and

B is a 4- to 8-membered cycloalkyl ring, a 4- to 10-membered heterocycle or a 6- to 10-membered aryl ring;

or a physiologically acceptable salt thereof.

2. The compound according to claim 1 , wherein

B is a 4- to 8-membered cycloalkyl ring;

or a physiologically acceptable salt thereof.

3. The compound according to claim 1 , wherein

R2 and R3 are H;

R4 is (C 1 -C 6 )-alkyl, O—(C 1 -C 6 )-alkyl, or (C 0 -C 6 )-alkylene-aryl;

R5 is H; and

B is a 4- to 8-membered cycloalkyl ring;

or a physiologically acceptable salt thereof.

4. A pharmaceutical composition comprising the compound according to claim 1 or a physiologically tolerated salt thereof, in combination with a pharmacologically acceptable carrier or excipient.

5. A pharmaceutical composition comprising the compound according to claim 2 or a physiologically tolerated salt thereof, in combination with a pharmacologically acceptable carrier or excipient.

6. A pharmaceutical composition comprising the compound according to claim 3 or a physiologically tolerated salt thereof, in combination with a pharmacologically acceptable carrier or excipient.

7. The pharmaceutical composition according to claim 4 , further comprising one additional active ingredient.

8. The pharmaceutical composition according to claim 7 , wherein the additional active ingredient is selected from the group consisting of antidiabetics, hypoglycemic active ingredients, HMGCoA reductase inhibitors, cholesterol absorption inhibitors, PPAR gamma agonists, PPAR alpha agonists, PPAR alpha/gamma agonists, PPAR delta agonists, fibrates, MTP inhibitors, bile acid absorption inhibitors, CETP inhibitors, polymeric bile acid adsorbents, LDL receptor inducers, ACAT inhibitors, antioxidants, lipoprotein lipase inhibitors, ATP-citrate lyase inhibitors, squalene synthetase inhibitors, lipoprotein(a) antagonists, HM74A receptor agonists, lipase inhibitors, insulins, sulfonylureas, biguanides, meglitinides, thiazolidinediones, α-glucosidase inhibitors, active ingredients which act on the ATP-dependent potassium channel of the beta cells, glycogen phosphorylase inhibitors, glucagon receptor antagonists, activators of glucokinase, inhibitors of gluconeogenesis, inhibitors of fructose-1,6-biphosphatase, modulators of glucose transporter 4 , inhibitors of glutamine-fructose-6-phosphate amidotransferase, inhibitors of dipeptidylpeptidase IV, inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 , inhibitors of protein tyrosine phosphatase 1 B, modulators of the sodium-dependent glucose transporter 1 or 2 , GPR40 modulators, inhibitors of hormone-sensitive lipase, inhibitors of acetyl-CoA carboxylase, inhibitors of phosphoenolpyruvate carboxykinase, inhibitors of glycogen synthase kinase-3 beta, inhibitors of protein kinase C beta, endothelin-A receptor antagonists, inhibitors of I kappaB kinase, modulators of the glucocorticoid receptor, CART agonists, NPY agonists, MC4 agonists, orexin agonists, H3 agonists, TNF agonists, CRF agonists, CRF BP antagonists, urocortin agonists, β3 agonists, CB1 receptor antagonists, melanocyte-stimulating hormone agonists, CCK agonists, serotonin reuptake inhibitors, mixed serotoninergic and noradrenergic compounds, 5HT agonists, bombesin agonists, galanin antagonists, human growth hormones, growth hormone-releasing compounds, diphenylazetidinone derivative, TRH agonists, uncoupling protein 2 or 3 modulators, leptin agonists, DA agonists (bromocriptine, Doprexin), lipase/amylase inhibitors, PPAR modulators, RXR modulators, TR-β agonists and amphetamines.

9. A process for producing a pharmaceutical composition comprising the compound according to claim 1 or a physiologically tolerated salt thereof, in combination with a pharmacologically acceptable carrier or excipient, comprising mixing the compound according to claim 1 or the physiologically tolerated salt thereof with the pharmacologically acceptable carrier or excipient, and converting this mixture into a form suitable for administration.